Chugai Pharmaceutical Co., Ltd. announced changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting
scheduled on March 29, 2022. Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting growth strategy "TOP I 2030" under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors.
Name: Hisafumi Yamada, New Title: Director, Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, Translational Research, Clinical Development, and Pharmaceutical Technology. Current Title: Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, and Translational Research. Name: Toshiaki Itagaki, New Title: Director, Executive Vice President Chief Financial Officer (CFO)
Supervisory responsibility for Finance & Accounting, Corporate Communication, and Purchasing Head of Finance Supervisory Div. Current Title: Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, and Digital Transformation
Head of Finance Supervisory Div. Effective Date: March 29, 2022.